ChiCTR2600127006 Blinatumomab Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines ChiCTR2600127006—A multicenter, phase II randomized controlled trial comparing the efficacy and safety of 14-day short-course blinatumomab combined with short-cycle chemotherapy versus standard chemotherapy in adult patients with newly diagnosed Ph-negative B-cell acute lymphoblastic leukemia—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why ChiCTR2600127006 is a hot trial to watch

Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. ChiCTR2600127006 is notable because it evaluates Blinatumomab in a Phase 2 design while Flow cytometry serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Not reported, masking is Open Label, and the intervention model is Parallel Assignment. Planned enrollment of 26 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: Flow cytometry (Day 28±2 of induction therapy (Week 4))
• Secondary: Regular monitoring of disease recurrence, progression, secondary malignancies and all-cause mortality was conducted through peripheral blood tests, bone marrow evaluation, flow cytometric MRD detection, imaging examination and molecular indicators, to analyze the 1–2 year disease-free survival (DFS). (Disease-free survival (DFS) is calculated from the date when patients achieve remission. Regular follow-up is conducted at 1 and 2 years after the completion of treatment. Any endpoint event occurring during the entire follow-up period shall be recorded immediately.)
• Secondary: Bone marrow cytology examination (The time length from the initiation of medication to death)
• Secondary: According to the WHO and adult ALL response criteria, bone marrow aspiration, morphological examination, peripheral blood routine and cell morphology detection were performed.CR/CRh was comprehensively evaluated by flow cytometry, cytogenetics and molecular biology indexes. (CR/CRh was assessed by bone marrow morphology, peripheral blood and laboratory indicators at Day 28±2 of induction, after each consolidation cycle, before maintenance, and at 12/24-month follow-up.)
• Secondary: Clinical testing (During induction treatment)

Benchmark readouts in the surrounding field

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)
• A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women (Phase 2): Interval From First Dose to Evidence of Ovulation.(Mean) = 2.67 Number of days (Standard Deviation, 1.53); Interval From First Dose to Evidence of Ovulation.(Mean) = 4.0 Number of days (Standard Deviation, 0)
• A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (Phase 2): Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -0.4 percent change (Standard Error, 0.91); Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -9.4 percent change (Standard Error, 1.60)

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Blinatumomab (Approved; CD19 x CD3)

Company & Deal Intelligence context: Henan Cancer Hospital — China — http://www.anti-cancer.com.cn; Henan Provincial Cancer Hospital — China — https://www.anti-cancer.com.cn

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

ChiCTR2600127006 is a focused lens on Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia development. Its value will be determined by whether Blinatumomab can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.